Schrödinger: An Interesting Investment With Immense Potential
Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
The American Journal of Managed Care5h
Pursuit of ADCs in Bladder Cancer Comes With Questions About Toxicity, Cost
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
DOGE Targeting Non-DEI Staff, Starting With Probationary Workers—Reports
Most dismissals have been tied to the president's anti-DEI agenda. However, recent reports indicate that workers in non-DEI roles, who DOGE deems affiliated with DEI initiatives, have lost their jobs ...
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...
ophthalmologytimes10h
MediPrint Ophthalmics moves forward with LL-BMT1, sustained drug delivery contact lenses for glaucoma
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Iconic 60-year-old company that transformed America edges towards oblivion - because of Ozempic
A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript
Q3 2025 Earnings Call Transcript February 13, 2025 Operator: And good day. Thank you for standing by. Welcome to VistaGen ...
FiercePharma23h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...
AFP18h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...
The Times of Northwest Indiana21h
Quantum company redeveloping U.S. Steel's South Works site reaches validation phase
The quantum computing firm that's looking to redevelop the former U.S. Steel South Works advanced to the final stage of a Department of Defense quantum computing program.